<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841515</url>
  </required_header>
  <id_info>
    <org_study_id>NCT00134031</org_study_id>
    <nct_id>NCT01841515</nct_id>
  </id_info>
  <brief_title>Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug</brief_title>
  <official_title>Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulsan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulsan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD
      patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin
      (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in
      vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro
      platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The
      investigators designed a prospective study to evaluate the effect of desmopressin on platelet
      function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who
      were taking antiplatelet drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>collagen-epinephrine closure time</measure>
    <time_frame>1 hour</time_frame>
    <description>In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding after procedure</measure>
    <time_frame>1-4 hr after procedure</time_frame>
    <description>we observe incidence of bleeding complication after procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bleeding</condition>
  <condition>Tachycardia</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin administration</intervention_name>
    <arm_group_label>Desmopressin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult uremic patients with one or more antiplatelet medication,

          -  prolonged collagen/epinephrine (CEPI) closure time,

          -  need for emergent hemodialysis and

          -  subsequent catheter insertion

        Exclusion Criteria:

          -  acute coronary syndrome,

          -  hemophilia, and nephrogenic diabetes insipidus,

          -  allergy against desmopressin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulsan</investigator_affiliation>
    <investigator_full_name>Soon Bae Kim, M.D., PhD.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

